Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry? by Font, R. et al.
1.ID: ANNONC CuSlomer A 10: MOXOOG �fled by: PR Manu&<ript ea-. Original artlole C""""'• M; OP-At 
10 
20 
25 
30 
35 
ESMJ--..,,.. ....... .. ,_
ORIGINAL ARTICLE 
AnnolsolOncofogyOO: 1-5.2017 
d<>i: 10.1093/annonc/md,006 
Adherence to capecitabine in preoperative treatment 
of stage II and Ill rectal cancer: do we need to worry? 
R. Font
1
, J. A. Espinas
1
, L. layos2, M. Martioez Villacamria
3, J. Capdevila
4
, M. Tobeiia5, A. Pisa
6
, 
C. Pertea/, C. Lezcand\ E. fort
9
, I. Cardona 1
0
, N. Berga 11. J.1Sola1 & J.M. B0rras'·12* 
'Biomedical Research Institute, Bellvitge, (IDIBELL) - L'Hospitalel de LLob, Barcelona; 1Medical Oncology Service, Catalan Institute of Oncology, ICO Badalona. 
Barcelona; 'Medical Oncology Department, Ca1alan lnstilute or Oncology, !CO L'Hospitalet de llob, Barcelona; 'Medic.ii Oncology Department. Hospital Vall 
d'Hebron. VHIO, Barcelona; 'Medic.ii Oncology Se1Vice. Hospital Santa Creu i Sant Pau. Barcelona; 6Medical Oncology Service, Consorci Sanitari de Terrassa.
Tem,ssa, 8arcefona; 'Medical Oncology Service, Hospital Pare Taulf. Sabadell. Barcelona; "clinical Pharmacy Seivice, Hospital Germans Trias i Pujol, Badalona. 
Barcelona; 9Clinical Pharmacy Service, ICO l'Hospitalet de llob, Barcelona; 10cllnic.il Pharmacy Unit. Hospital Vall <fHebron, Barcelona; ''Clinical Pharmacy 
Service, Hospital Sta. Creu i Sant Pau. Barcelona; "Department of Clln<caf Sciences, Unlversitat of Barcelona. 8arcefona, Spain 
'Co«espondence to: Dr Josep M. Borras, Department of Clinical Sciences, Univers�y of Barcelona. Gran Via 199-203, la Planta, 08908-Hospitalet, Barcelona, Spain, 
Tel: + 34·932607820; E-mail: jmborras@vb.edu 
Background: Preoperative oral capeotabine plus radiotherapy has been progressively adopted in oncology units to provide 
more convenient care to patients with rectal cancer, but little is known about adherence to this therapy. 
Patients and methods: Prospective, multicentre obseNational study in six hospitals in metropolitan Barcelona (Spain), in 
patients with stage II and Ill rectal cancer. Assessment of adherence was based on the medical report in the clinical history, a 
patient questionnaire and a pill count in the pharmacy service upon finalization of treatment. Patients were considered 
adherent if they had taken 80%-l l 0% of the prescribed treatment. We evaluated clinical variables, adverse effects, anxiety and 
depression (using the hospital anxiety depression scale [HADS]), and quality of life (EORTC QLQ-30). We analysed adherence· 
associated variables using a logistic regression model and concordance between adherence measures by means of the modi­
fied Kappa index. 
Results: We included 119 participants. Adherence measures showed little concordance between the assessment methods 
used: adherence was 100% according to the clinical history, 83.2% according to self-report and 67.9% according to the pill 
count. In the multivariable analysis, the most relevant variable associated with non-adherence was anxiety prior to treatment 
(adjusted odds ratio (ORa] 6.96, 95% confidence inteNal (Cl) l .48, 32.7). We did not obseNe any relevant association between 
adherence and clinical variables and baseline quality of life parameters. 
Conclusions: Adherence to short-term oral neoadjuvant treatment in rectal cancer may be a clinical problem, and it should 
be acknowledged and systematically evaluated by clinicians during treatment. The limited concordance between different 
measures of adherence highlights the challenges in monitoring it and the need to use different approaches to assess its 
impact in clinical practice. 
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Introduction 
40 Combination radiochemotherapy for stage II and III rectal cancer 
is a therapeutic standard [ 1], with oral capecitabine normally ad­
ministered as an adjunct to radiotherapy, but this option also 
raises the question of therapeutic adherence. 
treating physician ( 2 J. One very relevant aspect of research on 
therapeutic adherence is its measurement, as there is no validated 
instrument that helps to standardise its quantification [2). In 
fact, the results of different evaluations on adherence depend in 
part on how it is assessed [3), with a considerable variety of meth- so 
ods to choose from [ 4 J. 
Adherence is the degree to which patient behaviour corres-
4S ponds to the therapeutic recommendations agreed on with the 
One little-studied area in adherence research is preoperative 
treatment for rectal cancer with capecitabinc. 'The fact that this is 
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a short-term, oral treatment given prior to surgery suggests that 
adherence should be high [SJ. The aim of this study is to evaluate 
adherence in this clinical situation in a prospective, multi­
hospital cohort, using different methods to measure adherence. 
Patients and methods 
This was a prospective study and included patients diagnosed with inci­
dent, stage JI and III rectal cancer, with an indication for treatment with 
capecitabine and radiotherapy as a neoadjuvant treatment to surgical 
intervention. Six hospitals in the Barcelona area participated between 
10 June 2012 and March 2014. Patients signed informed consent upon en­
rolment, and the study was approved by the Ethics Clinical Research 
Committee at the BeUvitge Hospital. Participants were followed up 
throughout the neoadjuvant treatment (5-o weeks} or until definitive 
suspension of treatment due to disease progression, 1oxkity or patient 
15 decision. We excluded patients participating in clinical trials. Assuming 
an 80% adherence rate to the treatment in our population, we calculated 
needing a sample size of 102 to estimate adhere.nee with 95% confidence 
and a precision of:!: 5%. We anticipated a replacement rate of 10%. 
Variables and source of data were obtained using the following: The re-
20 view of the clinical record was the source for information on tumour 
characteristics, stage and treatment. The questionnaire on patient­
reported symptoms and adverse effects consisted of a specific List, revised 
by the investigating clinicians. Participants also responded to questions 
about comorbidities and the number of medicines they were taking in 
25 addition to the chemotherapy. 
The Simplified Medication Adherence Questionnaire (SMAQ} [ 6J eli­
cited information about participants' habits for taking medication, pro­
pensity to skip doses, timetables, adverse effects, omissions at the 
weekend and quantification over the previous week. Specially trained 
30 medical professionals administered the questionnaire. We categorised 
patients as non-adherent if their response to one or more questions on 
adherence was negative. The average pill count on dispensed and re­
turned medication was carried out in the hospital pharmacy during 
planned appointments for prescription refills. Adherence was calculated 
35 from the number of pills prescribed, the pills returned and the days of 
treatment. Patients were categorised as adherent if they took� 80% [7]. 
We evaluated participants' emotional state (depression and anxiety) 
using HADS, which is self-administered and has been validated in our 
country [8]. We also used the EORTC QLQ-C30, a validated tool for as-
40 sessing quality oflife in cancer patients over the previous week; it consists 
of 30 questions or items related to physical, emotional, social and func­
tional aspects [ 9 J. 
To analyse the determinants of non-adherence to oral treatment, we 
calculated the odds ratio (OR) and its 95% confidence interval (CI} using 
45 non-conditi.ooal logistic regression models. In order to predict adher­
ence, we have restricted the statistical analysis to pre-treatment variables. 
Each variable whose univariate test has shown a P value of less than 0.25 
were adjusted for clinical variables (age, sex and stage) ( 10]. The degree 
of concordance between the three methods used 10 measure adherence 
5-0 was estimated using the modified Kappa statistic ( 11 ]. We used the SPSS 
statistical package (version 21.0). 
Results 
One hundred nineteen participants were included in the study. 
Supplementary Figure SI (available at Annals of Oncologyonline)
ss presents the flow chart for participants during the course of the 
study. 
Table I shows the characteristics of the patients. There were 
76.3% of these with comorbidity; hypertension was the most fre­
quent condition. All patients received concomitant radiotherapy, 
21 font et al. 
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Table 1. Description of the study sample participants characteristics 
N(%) 
Sex Men 76(63.9) 
Women 43 (36.1) 
Age at diagnosis Mean(SD) 64.7 (10.0) 
<SS 20 (16.8) 
55-64 37 (311) 
65-74 47 (39.S) 
;,:75 15 (12.6) 
BMI at diagnosis Mean(SO) 28.5 (11.1) 
Normal weight 35 (29.4) 
Overweight 44 (370) 
Obese 31 (26.1) 
Missing 9 (7.S) 
Karnosfky grade (96) Mean(SO) 90.7 (11.2) 
ECOGgrade 0 40(33.6) 
1 66(55.S) 
2 I (0.8) 
Missing 12 (10.1) 
Clinical stage IIA 12 (10.1) 
IIIA 11 (92) 
1118 54 (45.4) 
Ill( 42 (35.3) 
Edvcatlonal level• Illiterate 17 (14.4) 
Primary school 61 (51.7) 
education 
Secondary school 19(16.1) 
education 
Higher education 12(102) 
Missing 9(7.6) 
Person(s) administering Patient 95 (80.S) 
medkation" Family 8(6.8) 
Patient and family 13 (11.0) 
Missing 2 (1.7) 
Comorbidity• No 28 (23.7) 
(multiple choice) Yes 90(76.3) 
Cardlopathy 9(10.o) 
High blood pressure 61 (67.8) 
Diabetes 21 (23.3) 
Migh cholesterol 47 (52.2) 
Depression 14 (15.6) 
Others 18(20.0) 
Polymedication• 0 17 (14.4) 
1-4 77 (6S.3) 
5-10 22 (186) 
+ 10 2 (1.7) 
Radiotherapy" 118(100.0) 
Total dose applied 45Gy 56(47.5) 
50.4Gy 57 (48.3) 
Others S (42) 
Temporary inte11uption Yes 25 (21.2) 
of treatment No 93 (78.8) 
Chemotherapy" 118 (100.0) 
Temporary inte11uption Yes 7 (5.9) 
of treatment No 111 (94.1) 
Definitive suspension Yes 5(4.2) 
of treatment No 113(95.8) 
Reason for discontinuing Toxicity 4 (80.0) 
treatment Other: perforated 1 (20.0) 
duodenal ulcer 
•Participant-report questionnaire (N = 118). 
bReview of the clinical record-follow-up (N = 118). 
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and 116 finally underwent surgery; the other 2 patients could not 
due to disease progression. With regard to capecitabine treat­
ment, this was temporarily interrupted in seven patients (5.9%) 
and definitively in five (4.2%) due to toxicity. 
Table 2. Description of adherence measures 
% Adherence Concordance 
Physician report SMAQ 
Physician report 100 
SMAQ 83.2 
Refill hospital 
pharmacy 
67.9 
N=1070.82" 
N=1090.56• N=102 0.40' 
Interpretation of Kappa:<0: poor; 0.01-0.20: slight; 0.21-0.40: fair; 0.41-
0.60: moderate; 0.61-0.80: substantial; 0.81-0.99: almost perfect. 
•concordance: alternative chance-corrected statistic to kappa. 
Overall, physicians' reports did not include any mention of 5 
non-adherence, whereas adherence was 83.2% according to the 
SMAQ questionnaire and 67.9% according to the pill count in 
the hospital pharmacy. Thus, the degree of concordance was very 
high between the clinical history and the SMAQ but more moder-
ate with the pill count (Table 2). 10 
The univariable and multivariable analyses with the different 
independent variables in relation to adherence (measured by pill 
count) are presented in Table 3, along with the percentage of ad­
herents according to the categories of each variable. In the multi­
variable analysis, we did not observe an association between ts 
adherence and any of the demographic or disease-related vari­
ables. With regard to the HADS, we observed that participants 
with low levels of anxiety at treatment initiation were seven times 
as adherent as participants with high levels (OR 6.96, 95% CI 
1.48, 32.70). There was also a significant, although lower magni- 20 
tude, association for depression and anxiety together; partici­
pants with a higher global score at treatment initiation were less 
adherent (Table 3). The EORTC QLQ-30 pre-treatment did not 
bring to light any significant association for global quality oflife. 
Table 3. Association between adherence (pill count) and pre-treatment study variables: prevalence and odds ratio 
N=109 N (% adherents) OR(95%CI) 0Ra(95%CI) 
Sex Men 69(63.8) 1 
Women 40(75.0) 1.71 (0.72-4.06) 2.14 (0.80-5.73) 
Age at diagnosis :554 19(52.6) I 1 
55-64 33 (75.8) 2.81 (0.85-9.36) 2.95 (0 78-1 1.2) 
�65 57 (68.4) 1.95 (0.68-5.63) 1.77 (0.56-5.57) 
Clinkal stage 11-IIIA 22 (68.2) 1 1 
IIIB-IIIC 87 (67.8) 0. 98 (036-2.68) 0.90 (0.28-2.86) 
Pathological stage 0 18 (72.2) 1 1 
29(75.9) 1.21 (0.32-4.60) 1.12 (0.25-5.00) 
II 29(62.1) 0.63 (0.18-2.25) 0.60 (0.13-2.72) 
Ill 29(65.5) 0.73 (0.20-0.264) 1.13 (0.27-4.72) 
IV 2 (100.0) 
Tumour site Distal rectum 33 (72.7) 1 1 
Middle rectum 42 (61.9) 0.61 (0.23-1.64) 0.26 (0.07-1.00) 
Proximal rectum 32 (75.0) 1.13 (0.37-3.41) 0.89 (0.23-3.51) 
Symptoms at diagnosis, clinical history None 2 (100.0) 
1-2 48 (72.9) 1 
+3 59 (62.7) 0.63 (0.27-1.43) 034 (0.11 a 1.02) 
Symptoms at diagnosis Rectal bleeding 86(67.4) 0.91 (0.34-2.45) 0.64 (0.20-2.08) 
Rectal tenesmus 49 (65.3) 0.81 (0 36-1.81) 0.97 (0.38-2.49) 
Constipation 19 (73.7) 1.40 (0.0.46-4.25) 1.69 (0.44-6.43) 
Abdominal pain 22 (59.1) 0.62 (0.23-1.62) 0.59 (0.16-2.13) 
Constitutional syndrome 12 (50.0) 0.43 (0.13-1.43) 0 21 (0.04-1.00) 
Polymedication 0 16(68.8) 1 1 
1-4 70 (68.6) 0.99 (0.31-3.20) 0.97 (0.25-3.72) 
5-10 20 (70.0) 1.06 (0.26-4.41) 0.85 (0.16-4.43) 
+10 2 (0.0) 
HADS anxiety (scale 0-21) No symptoms of anxiety (<8 points) 70 (75.7) 3.64 (1.07-12.3) 6.96 (1.48-32.7) 
BOl'deline (8-1 o points) 25 (56.0) 1.48 (0.39-5.71) 1.70 (0.31-9.40) 
Symptoms of anxiety(� t 1 points) 13 (46.2) 
HAOS depression (scale 0-21) No symptoms of depression ( <8 points) 101 (69.3) 1 1 
Borderline (8-10 points) 3 (66.7) 0.89 (0.08-10. I) 1.08 (0.07 - 17.7) 
Symptoms of depression(> 11 points) 4(25.0) 0.1 S (0.02-1.48) 0.15 (0.01 - 1.66) 
Continued 
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Table 3. < .,,,1m11i-,J 
N=109 
HADS 
EORTC QLQ-C30, mean (SD) (scale 0-100) Global quality of life 
Physical function 
Social function 
Emotional function 
Cognitive function 
Role function 
Fatigue 
Nausea and vomiting 
Pain 
Dyspnoea 
Insomnia 
Loss of appetite 
Constipation 
Diarrhoea 
Economic impact 
N (% adherents) OR(95%CI) 
Mean(50) OR(95%CI) 
8.3 (5.6) 0.92 (0.86-0.98) 
75.5 (16.4) 1.02 (1.00-1.04) 
94.2 (9.8) 1.03 (1.00-1.06) 
92.2 (14.5) 1.00 (0.98-1.03) 
78.2 (18.7) 1.01 (0.99-1.03) 
92.9(12.1) 1.02 (1 .00-1.04) 
95.0 (14.4) 1.02 ( 1.00-1.04) 
12.2 (17.Z) 0.98 (0.96-1.00) 
1.1 (5.1) 0.95 (0.90-1.00) 
12.1 (16.3) 0.98 (0.96-1.00) 
4.1 (11.0) 1.00 (0.97-1.03) 
24.2 (31.6) 1.00 (0.99-1.01) 
7.3 (16.0) 0.98 (0.96-1.00) 
15.5 (25.5) 0.99 (0.98-1.01) 
16.9 (24.9) 0.98 (0.97-1.00) 
137(19.9) 0.98 (0.96-1.00) 
A.nr,als of 011co1ogy 
0Ra(95%CI) 
ORa (95%CI) 
0.89 (0.82--0.97) 
1.02 (0.99-1.04) 
1.04 ( 1.00-1.08) 
1.01 (0.97-1.04) 
1 .02 (0.99-1.04) 
1.03 (1.00-1.05) 
1.01 (0.98-1.04) 
0.98 (0.95-1.00) 
0.93 (0 87-0.99) 
0.98 (0.95-1.00) 
1 00 (0.97-1.03) 
1.00(0.98-1.02) 
0.98 (0.95-1.00) 
0.99 (0.97-1.01) 
0.99 (0.97-1.01) 
0.97 (0.95-1.00) 
OR, odds ratio; ORa, odds ratio adjusted for sex. age at diagnosis and clinical stage; Cl, confidence interval. 
Discussion 
The main finding of this study is the different result for adherence 
to preoperative chemotherapy with capecitabine in the context of 
radiochemotherapy for rectal cancer, according to the method of 
s assessment. Adherence varied from 100% (clinical history) to 
83.2% (self-report) to 67.9% ( pill count). We know that self­
report tends to overestimate adherence compared to indirect 
methods that do not depend on patient opinion [ 12), in part due 
to s<>cial desirability bias [ 13), wherein patients respond in the 
10 way they believe will please the health professional evaluating 
them. Patients and professionals may also have different percep­
tions regarding what adherence means. 
The data on adherence observed in this study are consistent 
with the range of values observed in previous studies [4]. In a 
1s sample of 24 participants with rectal cancer, Figueiredo ( 14.] 
measured adherence by means of pill count, finding that 94.3% 
were adherent. In a single-site intervention study, evaluating the 
impact of pharmaceutical care, also in 24 participants with colo­
rectal cancer, Simmons et al. [ LS J observed an adherence rate of 
20 87.2% in the control group and 96.8% in the intervention group, 
using electronic monitoring as the method of assessment. 
Bhattachayn et al. [ 16) measured adherence with self-report in 
colorectal and breast cancer patients, reporting a 72.7% rate of 
adherence, while an intervention study in Germany ( 17] observed 
25 a rate of 79.5% in the pre-intervention phase, using electronic 
monitoring. Globally, these data are similar to those we obtained 
when using self-report, and better than those obtained through 
pill counts. Our results show the need for health professionals to 
systematically evaluate therapeutic adherence as a routine part of 
30 the treatment process, once the reliability of the assessment 
method has been checked [ 18). Our failure to identify any pre­
dictive factors that would allow us to define a subgroup of pa­
tients at high risk for non-adherence, underlines the importance 
of systematic evaluation in all patients. Indeed, the association 
4 I Fort et al.
between sociodemographic or disease-related variables and poor 35 
adherence shows mixed results in recent literature reviews [4]. 
However, we did find a clear association for anxiety at treatment 
initiation, suggesting that this is a clinically manageable risk fac-
tor to take into account when detected. 
Some studies have shown how to improve adherence through 40 
pharmaceutical care and education strategies ( 17), and they also 
explore patient concerns about their disease, the need to have bet-
ter information about it, the potential adverse effects of treatment 
and how to manage them [ 16). These strategies, combined with 
discussions with patients about the medical aspects related to 45 
lTeatment and the disease prognosis, may be useful in reducing 
non-adherence to capecitabine. 
Some limitations of this study should be considered when in­
terpreting results. Physician-reported adherence was measured 
by means of a review of the data recorded in the clinical history. so 
However, this could lead to an underestimation of their capacity 
to detect a problem. In addition, our exclusion of patients 
involved in clinical trials could have eliminated a group of pa­
tients with different characteristics and hypothetically greater 
adherence. On the other hand, one noteworthy feature of this 55 
study, which attests to its representativeness to usual clinical 
practice, is its multicentre design and its complete lack of 
attrition. 
All in all, we observed notable differences in adherence ac­
cording to the measurement technique in rectal cancer patients 60 
who were candidates for treatment with radical intent with pre­
operative radiochemotherapy. Health professionals should 
assess adherence problems with the patient during the consult­
ation, especially the presence of anxiety at treatment initiation, 
in order to identify patients at risk of non-adherence. 65 
Pharmacists could also monitor the pill count at the end of the 
treatment and inform the physician about any adherence prob­
lems observed. 
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Key Message 
Annals ol Onco!Dgy 
Adherence to short-term oral neoadjuvant capecitabine in rectal cancer patients could be a clinical problem, and it should be acknowl­
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edged and assessed by health professionals during treatment.
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